Xolair

Xolair (omalizumab) is a prescription biologic used to help manage allergic asthma and chronic hives. It works by targeting immunoglobulin E (IgE) to reduce allergic reactions. This injectable therapy is designed for patients who have not responded adequately to other treatments. Always consult a healthcare provider for suitability.

Xolair (omalizumab) is used to treat moderate to severe persistent allergic asthma in patients aged 6 and older. It is also approved for chronic idiopathic urticaria (CIU), also known as chronic hives, in adults and adolescents 12 years and older. People with these conditions may use omalizumab when standard treatments have not provided sufficient relief.

Xolair (omalizumab) helps reduce the frequency and severity of asthma attacks and hive symptoms over time. Many patients report fewer flare-ups and improved daily comfort after starting treatment. Individual responses may vary based on condition and medical history.

Xolair (omalizumab) is given by injection under medical supervision. Patients should inform their doctor about all allergies, infections, or recent surgeries before starting treatment. Regular monitoring may be required to assess response and safety. Keep follow-up appointments as directed.

Xolair (omalizumab) has a low potential for drug interactions due to its targeted mechanism. However, it is important to inform your healthcare provider about all medications, including over-the-counter drugs and supplements. No major interactions with common asthma or allergy medications have been widely reported.